Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
04/2014
04/22/2014CA2611451C Solid preparation
04/22/2014CA2611295C Isoquinoline derivatives as inhibitors of rho-kinase
04/22/2014CA2608301C Pyrido[2,3-d]pyrimidines useful as hcv inhibitors, and methods for the preparation thereof
04/22/2014CA2597813C Chemical compounds
04/22/2014CA2591117C Novel heteroarylacetamides
04/22/2014CA2589992C Treatment of solid cancers
04/22/2014CA2589489C Method of providing fast relief to a user of a nicotine chewing gum
04/22/2014CA2589192C Phenyl-piperazin methanone derivatives
04/22/2014CA2585925C Tetrahydro-pyridinyl pyrazole cannabinoid modulators
04/22/2014CA2585855C Dye-free pharmaceutical suspensions comprising sorbitol as a non-reducing sweetener and at least one active agent
04/22/2014CA2585125C Salts of isophosphoramide mustard and analogs thereof as anti-tumor agents
04/22/2014CA2582339C Preventive and/or therapeutic agent for a storage disorder accompanying benign prostatic hyperplasia
04/22/2014CA2534897C Process of making flowable hemostatic compositions and devices containing such compositions
04/22/2014CA2507125C Ena nucleic acid pharmaceuticals capable of modifying splicing of mrna precursors
04/22/2014CA2471657C Methods for improving the aesthetic appearance of skin
04/22/2014CA2394357C Modified leukotoxin gene and protein
04/22/2014CA2345209C Antisense modulation of integrin .alpha.4 expression
04/17/2014WO2014059430A1 Delivery of small interfering rna and micro rna through membrane-disruptive, responsive nanoscalle hydrogels
04/17/2014WO2014059429A2 Small molecules inhibiting oncoprotein myc
04/17/2014WO2014059404A1 Anti-virulence compositions and methods
04/17/2014WO2014059383A1 Gsk3 inhibitors and methods of use thereof
04/17/2014WO2014059368A1 Companion diagnostics for tec family kinase inhibitor therapy
04/17/2014WO2014059367A1 Pharmaceutical compositions containing enantiomerically pure and/or racemic mixtures of chiral piperazine compounds and methods of terminating acute episodes of cardiac arrhythmia, restoring normal sinus rhythm, preventing recurrence of cardiac arrhythmia and maintaining normal sinus rhythm in mammals through administration of said compositions
04/17/2014WO2014059364A1 Methods of treating kennedy's disease
04/17/2014WO2014059363A1 Oral solution formulations of aripiprazole
04/17/2014WO2014059354A1 Pharmaceutical compositions containing piperazine compounds in combination with a p450 inhibitor and methods of terminating acute episodes of cardiac arrhythmia, restoring normal sinus rhythm, preventing recurrence of cardiac arrhythmia and maintaining normal sinus rhythm in mammals through administration of said compositions
04/17/2014WO2014059350A1 Open chained or fused 1,1 '-alkylene-bis-uracil derivatives, useful in skin uv-protection
04/17/2014WO2014059346A1 Methods for the treatment of conditions involving dopamine through administration of piperazine compounds
04/17/2014WO2014059338A1 Novel piperazine compounds, pharmaceutical compositions containing the same and methods of terminating acute episodes of cardiac arrhythmia, restoring normal sinus rhythm, preventing recurrence of cardiac arrhythmia and maintaining normal sinus rhythm in mammals
04/17/2014WO2014059333A1 Compounds that modulate intracellular calcium
04/17/2014WO2014059309A1 Pharmaceutical formulations of pilocarpine
04/17/2014WO2014059306A1 Pyrimidine hydroxy amide compounds as protein deacetylase inhibitors and methods of use thereof
04/17/2014WO2014059305A1 Compounds for treating rac-gtpase mediated disorder
04/17/2014WO2014059295A1 Use of mtor inhibitors to treat vascular cognitive impairment
04/17/2014WO2014059284A1 Method of preparing resin tinctures
04/17/2014WO2014059279A2 Materials and methods useful to treat neuroblastomas and pheochromocytomas
04/17/2014WO2014059265A1 Urea and amide derivatives of aminoalkylpiperazines and use thereof
04/17/2014WO2014059262A1 Method of determining an injected dose based on a known oral dose
04/17/2014WO2014059251A1 Enhancement of the immune response
04/17/2014WO2014059225A1 Cosmetic compositions containing at least one flavonoid and ferulic acid
04/17/2014WO2014059220A1 Glycosphingolipids and methods of use thereof
04/17/2014WO2014059214A1 Guanidine and amine substituted tetrahydroisoquinoline compounds as factor xia inhibitors
04/17/2014WO2014059203A1 Crystalline forms of a factor xia inhibitor
04/17/2014WO2014059202A1 Guanidine substituted tetrahydroisoquinoline compounds as factor xia inhibitors
04/17/2014WO2014059199A1 Hemoglobin-based oxygen carrier-containing pharmaceutical composition for cancer targeting treatment and prevention of cancer recurrence
04/17/2014WO2014059185A1 Amino - dihydrothiazine and amino - dioxido dihydrothiazine compounds as beta-secretase antagonists and methods of use
04/17/2014WO2014059158A1 Multifunctional radical quenchers
04/17/2014WO2014059157A1 Topical vitamin d oral supplement compositions
04/17/2014WO2014059151A1 Method and device for reducing dermal filler adverse events
04/17/2014WO2014059143A1 Topical vitamin d and ubiquinol oral supplement compositions
04/17/2014WO2014059135A1 Galactose-pronged carbohydrate compounds for the treatment of diabetic nephropathy and associated disorders
04/17/2014WO2014059117A1 Cd28 expression during lenalidomide immune modulation
04/17/2014WO2014059111A2 Method for increasing the oral bioavailability of a metabotropic glutamate 2/3 receptor antagonist
04/17/2014WO2014059095A1 Combinations
04/17/2014WO2014059022A1 Nanoparticles for targeted delivery of multiple therapeutic agents and methods of use
04/17/2014WO2014058979A2 Laquinimod for reducing thalamic damage in multiple sclerosis
04/17/2014WO2014058974A1 Methods of managing inflammation using glycolysis pathway inhibitors
04/17/2014WO2014058947A1 Compositions and methods for treating cancer using pi3k inhibitor and anti-cd19 maytansinoid immunoconjugate
04/17/2014WO2014058905A2 Potassium-binding agents for treating hypertension and hyperkalemia
04/17/2014WO2014058881A1 Methods for treatment of alport syndrome
04/17/2014WO2014058801A1 2'-chloro nucleoside analogs for hcv infection
04/17/2014WO2014058785A1 Combination therapy
04/17/2014WO2014058747A1 5-phenoxy-3h-pyrimidin-4-one derivatives and their use as hiv reverse transcriptase inhibitors
04/17/2014WO2014058742A1 Therapeutic treatment
04/17/2014WO2014058736A1 Neuroactive 19-alkoxy-17(20)-z-vinylcyano-substituted steroids, prodrugs thereof, and methods of treatment using same
04/17/2014WO2014058691A1 Inhibitors of irak4 activity
04/17/2014WO2014058685A1 Inhibitors of irak4 activity
04/17/2014WO2014058441A1 Method of weight management
04/17/2014WO2014058427A1 Method and compositions for treating psoriasis
04/17/2014WO2014058355A1 Method for the quantitive analysis of terminal nucleotides of a g chain of human telomeric dna
04/17/2014WO2014058343A1 Osteogenic bioresorbable material for the replacement of bone defects and method for producing same
04/17/2014WO2014058318A1 Infant nutrition with lipid globules to increase energy expenditure and metabolic flexibility later in life
04/17/2014WO2014058301A1 Infant nutrition with lipid globules to increase energy expenditure and metabolic flexibility later in life
04/17/2014WO2014058268A1 Monohydrate crystal of fimasartan potassium salt, method for preparing same, and pharmacological composition comprising same
04/17/2014WO2014058188A1 Combination drug comprising gemigliptin and metformin, and method for the preparation thereof
04/17/2014WO2014058160A1 Composition comprising myricetin as active ingredient for enhancing exercise performance or fatigue recovery
04/17/2014WO2014058114A1 Composition, containing cis-cyclo(l-leu-l-pro) or cis-cyclo(l-phe-l-pro), for use as an antimicrobial and antiviral agent, and preparation method therefor
04/17/2014WO2014058083A1 Composition containing poly-gamma glutamic acid for improving blood triglyceride levels
04/17/2014WO2014058078A1 Process for producing dihydro-2h-pyran derivatives
04/17/2014WO2014058071A1 Cyclopropanamine compound and use thereof
04/17/2014WO2014058047A1 Method for producing pharmaceutical preparation containing calcium antagonist/angiotensin ii receptor antagonist
04/17/2014WO2014058046A1 Pharmaceutical preparation containing calcium antagonist/angiotensin ii receptor antagonist
04/17/2014WO2014058035A1 Novel spirooxindole derivative and process for producing the same
04/17/2014WO2014058000A1 Serotonin 2b receptor antagonist
04/17/2014WO2014057995A1 Extract and formulation including extract
04/17/2014WO2014057957A1 Steroid compound, and medicine comprising same
04/17/2014WO2014057928A1 Skin patch
04/17/2014WO2014057772A1 Novel pyrazole derivative
04/17/2014WO2014057687A1 Antibody-drug conjugate
04/17/2014WO2014057522A1 Compositions and methods for treating non-alcoholic steatohepatitis
04/17/2014WO2014057511A1 Use of emicorons as selective inducers of damage to the telomere dna
04/17/2014WO2014057499A1 A process for manufacturing sterile brinzolamide ophthalmic suspension
04/17/2014WO2014057493A1 Astaxanthin derivatives for heat stress prevention and treatment
04/17/2014WO2014057435A1 Orexin receptor antagonists which are [ortho bi (hetero )aryl]-[2-(meta bi (hetero )aryl)-pyrrolidin-1-yl]-methanone derivatives
04/17/2014WO2014057415A2 Inhibitors of dna gyrase for the treatment of bacterial infections
04/17/2014WO2014057414A1 Ketamine derivatives
04/17/2014WO2014057408A1 Methods for increasing insulin sensitivity by agonists of serotonergic receptors 5-ht2
04/17/2014WO2014057365A1 Stable injectable pharmaceutical composition of epinephrine or salts thereof
04/17/2014WO2014057266A1 Acylpiperazines as inhibitors of transglutaminase and their use in medicine
04/17/2014WO2014057122A1 Pyrrolobenzodiazepine-anti-cd22 antibody conjugates
1 ... 302 303 304 305 306 307 308 309 310 311 312 313 314 315 316 317 318 319 320 321 322 ... 7860